Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21

Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination wi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 10; p. 879
Main Authors: Kweon, SoonHo, Phan, Minh-Trang Thi, Chun, Sejong, Yu, HongBi, Kim, Jinho, Kim, Seokho, Lee, Jaemin, Ali, Alaa Kassim, Lee, Seung-Hwan, Kim, Sang-Ki, Doh, Junsang, Cho, Duck
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 24-04-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination with a short exposure to soluble IL-21. In addition, we describe a possible mechanism of the NK cell expansion through the OX40 receptor-OX40 ligand axis which is dependent on NK cell homotypic interaction. K562-OX40L cells were generated by lentiviral transduction and were used as feeder cells to expand and activate NK cells from PBMCs in the presence of IL-2/IL-15. Soluble IL-21 was also added in various concentrations only once at the beginning of the culture. NK cells were expanded for 4-5 weeks, and the purity, expansion rate, phenotype and function (cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), cytokine production, CD107a degranulation) of these expanded NK cells were compared to those generated by using K562 feeder cells. The culture of NK cells with K562-OX40L cells in combination with the transient exposure to IL-21 highly enhanced NK cell expansion to approximately 2,000-fold after 4 weeks of culture, compared to a 303-fold expansion using the conventional K562 cells. Mechanistically, the OX40-OX40L axis between the feeder cells and NK cells as well as the homotypic interaction between NK cells through the OX40-OX40L axis were both necessary for NK cell expansion. The short exposure of NK cells to IL-21 had a synergistic effect with OX40 signaling for NK cell expansion. Apart from their enhanced expansion, NK cells grown with K562-OX40L feeder cells were similar to those grown with conventional K562 cells in regard to the surface expression of various receptors, cytotoxicity, ADCC, cytokine secretion, and CD107 degranulation. Our data suggest that OX40 ligand is a potent co-stimulant for the robust expansion of human NK cells and the homotypic NK cell interactions through the OX40-OX40L axis is a mechanism of NK cell expansion.
AbstractList Background: Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells ex vivo using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination with a short exposure to soluble IL-21. In addition, we describe a possible mechanism of the NK cell expansion through the OX40 receptor-OX40 ligand axis which is dependent on NK cell homotypic interaction.Methods: K562-OX40L cells were generated by lentiviral transduction and were used as feeder cells to expand and activate NK cells from PBMCs in the presence of IL-2/IL-15. Soluble IL-21 was also added in various concentrations only once at the beginning of the culture. NK cells were expanded for 4–5 weeks, and the purity, expansion rate, phenotype and function (cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), cytokine production, CD107a degranulation) of these expanded NK cells were compared to those generated by using K562 feeder cells.Results: The culture of NK cells with K562-OX40L cells in combination with the transient exposure to IL-21 highly enhanced NK cell expansion to approximately 2,000-fold after 4 weeks of culture, compared to a 303-fold expansion using the conventional K562 cells. Mechanistically, the OX40-OX40L axis between the feeder cells and NK cells as well as the homotypic interaction between NK cells through the OX40-OX40L axis were both necessary for NK cell expansion. The short exposure of NK cells to IL-21 had a synergistic effect with OX40 signaling for NK cell expansion. Apart from their enhanced expansion, NK cells grown with K562-OX40L feeder cells were similar to those grown with conventional K562 cells in regard to the surface expression of various receptors, cytotoxicity, ADCC, cytokine secretion, and CD107 degranulation.Conclusion: Our data suggest that OX40 ligand is a potent co-stimulant for the robust expansion of human NK cells and the homotypic NK cell interactions through the OX40-OX40L axis is a mechanism of NK cell expansion.
Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination with a short exposure to soluble IL-21. In addition, we describe a possible mechanism of the NK cell expansion through the OX40 receptor-OX40 ligand axis which is dependent on NK cell homotypic interaction. K562-OX40L cells were generated by lentiviral transduction and were used as feeder cells to expand and activate NK cells from PBMCs in the presence of IL-2/IL-15. Soluble IL-21 was also added in various concentrations only once at the beginning of the culture. NK cells were expanded for 4-5 weeks, and the purity, expansion rate, phenotype and function (cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), cytokine production, CD107a degranulation) of these expanded NK cells were compared to those generated by using K562 feeder cells. The culture of NK cells with K562-OX40L cells in combination with the transient exposure to IL-21 highly enhanced NK cell expansion to approximately 2,000-fold after 4 weeks of culture, compared to a 303-fold expansion using the conventional K562 cells. Mechanistically, the OX40-OX40L axis between the feeder cells and NK cells as well as the homotypic interaction between NK cells through the OX40-OX40L axis were both necessary for NK cell expansion. The short exposure of NK cells to IL-21 had a synergistic effect with OX40 signaling for NK cell expansion. Apart from their enhanced expansion, NK cells grown with K562-OX40L feeder cells were similar to those grown with conventional K562 cells in regard to the surface expression of various receptors, cytotoxicity, ADCC, cytokine secretion, and CD107 degranulation. Our data suggest that OX40 ligand is a potent co-stimulant for the robust expansion of human NK cells and the homotypic NK cell interactions through the OX40-OX40L axis is a mechanism of NK cell expansion.
Background: Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells ex vivo using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination with a short exposure to soluble IL-21. In addition, we describe a possible mechanism of the NK cell expansion through the OX40 receptor-OX40 ligand axis which is dependent on NK cell homotypic interaction. Methods: K562-OX40L cells were generated by lentiviral transduction and were used as feeder cells to expand and activate NK cells from PBMCs in the presence of IL-2/IL-15. Soluble IL-21 was also added in various concentrations only once at the beginning of the culture. NK cells were expanded for 4–5 weeks, and the purity, expansion rate, phenotype and function (cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC), cytokine production, CD107a degranulation) of these expanded NK cells were compared to those generated by using K562 feeder cells. Results: The culture of NK cells with K562-OX40L cells in combination with the transient exposure to IL-21 highly enhanced NK cell expansion to approximately 2,000-fold after 4 weeks of culture, compared to a 303-fold expansion using the conventional K562 cells. Mechanistically, the OX40-OX40L axis between the feeder cells and NK cells as well as the homotypic interaction between NK cells through the OX40-OX40L axis were both necessary for NK cell expansion. The short exposure of NK cells to IL-21 had a synergistic effect with OX40 signaling for NK cell expansion. Apart from their enhanced expansion, NK cells grown with K562-OX40L feeder cells were similar to those grown with conventional K562 cells in regard to the surface expression of various receptors, cytotoxicity, ADCC, cytokine secretion, and CD107 degranulation. Conclusion: Our data suggest that OX40 ligand is a potent co-stimulant for the robust expansion of human NK cells and the homotypic NK cell interactions through the OX40-OX40L axis is a mechanism of NK cell expansion.
Author Kweon, SoonHo
Yu, HongBi
Lee, Jaemin
Kim, Jinho
Ali, Alaa Kassim
Lee, Seung-Hwan
Cho, Duck
Doh, Junsang
Kim, Seokho
Phan, Minh-Trang Thi
Kim, Sang-Ki
Chun, Sejong
AuthorAffiliation 6 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa , Ottawa, ON , Canada
10 Stem Cell and Regenerative Medicine Institute, Samsung Medical Center , Seoul , South Korea
3 Department of Laboratory Medicine, Chonnam National University , GwangJu , South Korea
1 School of Interdisciplinary Bioscience and Bioengineering (I-Bio), POSTECH , Pohang , South Korea
9 Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
5 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology , Daejeon , South Korea
4 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University , Seoul , South Korea
7 Laboratory Animal Science, Department of Companion, Kongju National University , Yesan , South Korea
8 Department of Materials Science and Engineering, Seoul National University , Seoul , South Korea
2 Department of Mechanical Engineering, POSTE
AuthorAffiliation_xml – name: 8 Department of Materials Science and Engineering, Seoul National University , Seoul , South Korea
– name: 10 Stem Cell and Regenerative Medicine Institute, Samsung Medical Center , Seoul , South Korea
– name: 1 School of Interdisciplinary Bioscience and Bioengineering (I-Bio), POSTECH , Pohang , South Korea
– name: 4 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University , Seoul , South Korea
– name: 9 Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
– name: 7 Laboratory Animal Science, Department of Companion, Kongju National University , Yesan , South Korea
– name: 2 Department of Mechanical Engineering, POSTECH , Pohang , South Korea
– name: 6 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa , Ottawa, ON , Canada
– name: 3 Department of Laboratory Medicine, Chonnam National University , GwangJu , South Korea
– name: 5 Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology , Daejeon , South Korea
– name: 11 Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University , Seoul , South Korea
Author_xml – sequence: 1
  givenname: SoonHo
  surname: Kweon
  fullname: Kweon, SoonHo
  organization: School of Interdisciplinary Bioscience and Bioengineering (I-Bio), POSTECH, Pohang, South Korea
– sequence: 2
  givenname: Minh-Trang Thi
  surname: Phan
  fullname: Phan, Minh-Trang Thi
  organization: Department of Mechanical Engineering, POSTECH, Pohang, South Korea
– sequence: 3
  givenname: Sejong
  surname: Chun
  fullname: Chun, Sejong
  organization: Department of Laboratory Medicine, Chonnam National University, GwangJu, South Korea
– sequence: 4
  givenname: HongBi
  surname: Yu
  fullname: Yu, HongBi
  organization: Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea
– sequence: 5
  givenname: Jinho
  surname: Kim
  fullname: Kim, Jinho
  organization: Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea
– sequence: 6
  givenname: Seokho
  surname: Kim
  fullname: Kim, Seokho
  organization: Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
– sequence: 7
  givenname: Jaemin
  surname: Lee
  fullname: Lee, Jaemin
  organization: Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
– sequence: 8
  givenname: Alaa Kassim
  surname: Ali
  fullname: Ali, Alaa Kassim
  organization: Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
– sequence: 9
  givenname: Seung-Hwan
  surname: Lee
  fullname: Lee, Seung-Hwan
  organization: Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
– sequence: 10
  givenname: Sang-Ki
  surname: Kim
  fullname: Kim, Sang-Ki
  organization: Laboratory Animal Science, Department of Companion, Kongju National University, Yesan, South Korea
– sequence: 11
  givenname: Junsang
  surname: Doh
  fullname: Doh, Junsang
  organization: Department of Materials Science and Engineering, Seoul National University, Seoul, South Korea
– sequence: 12
  givenname: Duck
  surname: Cho
  fullname: Cho, Duck
  organization: Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31105701$$D View this record in MEDLINE/PubMed
BookMark eNpVkUtr3DAUhUVJaR7NvquiZTee6v3YFMqQJkOGZtEGuhOyfTVxsKWpZIf239fzaEgEF4mjcz9ddM7RSUwREPpAyYJzYz-HbhimBSPULggx2r5BZ1QpUXHGxMmL8ym6LOWRzEtYzrl8h045pURqQs-Qu_qz9bF0KeIU8M00-Ii_3-Il9H3B96WLG3wrFTsKszlD2at3vwTB627jY4t39eMh5XFnSGXKgMeEV-uK0ffobfB9gcvjfoHuv139XN5U67vr1fLrumqEYmPVeh2ssVQrCQoU40FCUMDBeCmsrAljSgQtSSOA0CZYYiCAZjI0hFMj-AVaHbht8o9um7vB578u-c7thZQ3zuexa3pwtSQzWdWSmVYYXhtBTGNb4JpboaGdWV8OrO1UD9A2EMfs-1fQ1zexe3Cb9OSUsNQSNgM-HQE5_Z6gjG7oSjP_oI-QpuIY44xozZSereRgbXIqJUN4foYSt4vZ7WN2u5jdPua55ePL8Z4b_ofK_wFSUqNE
CitedBy_id crossref_primary_10_1007_s00109_021_02120_z
crossref_primary_10_1016_j_jcyt_2023_07_002
crossref_primary_10_1016_j_phrs_2020_104691
crossref_primary_10_3389_fimmu_2022_1044946
crossref_primary_10_1038_s41573_019_0052_1
crossref_primary_10_3390_cancers12030706
crossref_primary_10_1016_j_critrevonc_2021_103261
crossref_primary_10_3389_fimmu_2020_01851
crossref_primary_10_1016_j_omtm_2020_06_014
crossref_primary_10_3390_cells9040811
crossref_primary_10_1016_j_biopha_2023_115907
crossref_primary_10_1007_s00262_021_02982_9
crossref_primary_10_1021_acssensors_0c02138
crossref_primary_10_3390_cells13050451
crossref_primary_10_1002_mco2_422
crossref_primary_10_1016_j_mam_2020_100870
crossref_primary_10_1038_s41573_022_00413_7
crossref_primary_10_3389_fimmu_2022_841107
crossref_primary_10_3389_fimmu_2022_859177
crossref_primary_10_3389_fonc_2021_632540
crossref_primary_10_12677_ACM_2023_134719
crossref_primary_10_1186_s12943_022_01561_5
crossref_primary_10_1186_s40164_023_00431_0
crossref_primary_10_1016_j_jconrel_2022_01_049
crossref_primary_10_1007_s10404_022_02600_9
crossref_primary_10_1128_jvi_00372_22
crossref_primary_10_3389_fonc_2022_1062765
crossref_primary_10_2174_1574888X17666220107101722
crossref_primary_10_1002_cdt3_40
crossref_primary_10_1007_s00262_022_03322_1
crossref_primary_10_1016_j_omtm_2021_02_023
crossref_primary_10_3343_alm_2022_42_6_638
crossref_primary_10_3390_cancers15061743
crossref_primary_10_3389_fimmu_2022_953849
crossref_primary_10_3390_cancers13164129
crossref_primary_10_1016_j_drudis_2020_11_028
crossref_primary_10_1016_j_jcyt_2020_12_002
crossref_primary_10_1038_s41598_024_56297_7
crossref_primary_10_1038_s41423_021_00808_3
crossref_primary_10_3390_cancers13030577
crossref_primary_10_1186_s13045_019_0801_y
crossref_primary_10_3390_vaccines11010165
crossref_primary_10_1016_j_cyto_2021_155599
crossref_primary_10_1038_s41598_023_36200_6
crossref_primary_10_15789_1563_0625_MMS_1976
crossref_primary_10_3389_fonc_2023_1117781
crossref_primary_10_3390_jcm8101702
crossref_primary_10_1016_j_intimp_2022_109041
crossref_primary_10_3390_biomedicines9060662
crossref_primary_10_3389_fimmu_2021_648580
crossref_primary_10_3389_fimmu_2021_680611
crossref_primary_10_1016_j_tibtech_2023_03_018
crossref_primary_10_3390_cells10050967
crossref_primary_10_4049_jimmunol_2200422
crossref_primary_10_1002_adbi_202000195
crossref_primary_10_1007_s00432_023_05148_5
crossref_primary_10_3390_ijms23169426
crossref_primary_10_1111_imr_12793
Cites_doi 10.3343/kjlm.2009.29.2.89
10.1016/j.jcyt.2014.04.008
10.4049/jimmunol.168.10.4897
10.1146/annurev-immunol-030409-101243
10.1074/jbc.M110.137976
10.1182/blood-2004-12-4797
10.4049/jimmunol.176.10.5975
10.1158/1078-0432.ccr-12-1243
10.1073/pnas.0306567101
10.5045/br.2014.49.3.154
10.4049/jimmunol.167.2.875
10.1158/2326-6066.cir-17-0212
10.1158/0008-5472.can-12-2893
10.1007/978-1-4939-3684-7_14
10.1038/s41598-018-20656-y
10.1111/j.1600-065X.2009.00766.x
10.1016/j.jhep.2017.10.021
10.1080/2162402x.2016.1219007
10.1371/journal.pone.0030264
10.4049/jimmunol.150.5.1705
10.1615/CritRevImmunol.v29.i3.10
ContentType Journal Article
Copyright Copyright © 2019 Kweon, Phan, Chun, Yu, Kim, Kim, Lee, Ali, Lee, Kim, Doh and Cho. 2019 Kweon, Phan, Chun, Yu, Kim, Kim, Lee, Ali, Lee, Kim, Doh and Cho
Copyright_xml – notice: Copyright © 2019 Kweon, Phan, Chun, Yu, Kim, Kim, Lee, Ali, Lee, Kim, Doh and Cho. 2019 Kweon, Phan, Chun, Yu, Kim, Kim, Lee, Ali, Lee, Kim, Doh and Cho
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2019.00879
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
EndPage 879
ExternalDocumentID oai_doaj_org_article_b506e36b528d483b8408c9de373947ed
10_3389_fimmu_2019_00879
31105701
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Research Foundation of Korea
  grantid: 2015R1D1A1A09058740
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c462t-da7f9891765e6e623f5ef6e3e8a5495b02264f750c4e01cf908efe725fc031843
IEDL.DBID RPM
ISSN 1664-3224
IngestDate Tue Oct 22 15:12:01 EDT 2024
Tue Sep 17 21:25:59 EDT 2024
Sat Oct 26 01:41:31 EDT 2024
Thu Sep 26 18:24:43 EDT 2024
Sat Sep 28 08:28:31 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords natural killer cells
OX40 ligand
K562
IL-21
expansion
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-da7f9891765e6e623f5ef6e3e8a5495b02264f750c4e01cf908efe725fc031843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Eleanor Riley, University of Edinburgh, United Kingdom
These authors have contributed equally to this work
Reviewed by: Volker Huppert, Glycostem, Netherlands; Jacki Kornbluth, Saint Louis University, United States
This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal Frontiers in Immunology
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491902/
PMID 31105701
PQID 2232077267
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_b506e36b528d483b8408c9de373947ed
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6491902
proquest_miscellaneous_2232077267
crossref_primary_10_3389_fimmu_2019_00879
pubmed_primary_31105701
PublicationCentury 2000
PublicationDate 2019-04-24
PublicationDateYYYYMMDD 2019-04-24
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-24
  day: 24
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2019
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Lim (B13) 2014; 16
Granzin (B14) 2016; 5
Robertson (B2) 1993; 150
Croft (B18) 2010; 28
Croft (B19) 2009; 229
Nuebling (B8) 2018; 6
Pollmann (B15) 2018; 68
Baba (B20) 2001; 167
Kim (B12) 2010; 285
Soroosh (B21) 2006; 176
Phan (B9) 2016; 1441
Cho (B1) 2009; 29
Turaj (B7) 2018; 8
Imai (B4) 2005; 106
Park (B10) 2012; 32
Redmond (B22) 2009; 29
Lim (B11) 2013; 73
Bukczynski (B17) 2004; 101
Wen (B16) 2002; 168
Liu (B6) 2013; 19
Bae (B3) 2014; 49
Denman (B5) 2012; 7
References_xml – volume: 29
  start-page: 89
  year: 2009
  ident: B1
  article-title: Expansion and activation of natural killer cells for cancer immunotherapy
  publication-title: Korean J Lab Med
  doi: 10.3343/kjlm.2009.29.2.89
  contributor:
    fullname: Cho
– volume: 32
  start-page: 839
  year: 2012
  ident: B10
  article-title: Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells
  publication-title: Anticancer Res
  contributor:
    fullname: Park
– volume: 16
  start-page: 1419
  year: 2014
  ident: B13
  article-title: Effect of exposure to interleukin-21 at various time points on human natural killer cell culture
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2014.04.008
  contributor:
    fullname: Lim
– volume: 168
  start-page: 4897
  year: 2002
  ident: B16
  article-title: 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.10.4897
  contributor:
    fullname: Wen
– volume: 28
  start-page: 57
  year: 2010
  ident: B18
  article-title: Control of immunity by the TNFR-related molecule OX40
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-030409-101243
  contributor:
    fullname: Croft
– volume: 285
  start-page: 41755
  year: 2010
  ident: B12
  article-title: Homotypic cell to cell cross-talk among human natural killer cells reveals differential and overlapping roles of 2B4 and CD2
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.137976
  contributor:
    fullname: Kim
– volume: 106
  start-page: 376
  year: 2005
  ident: B4
  article-title: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
  publication-title: Blood
  doi: 10.1182/blood-2004-12-4797
  contributor:
    fullname: Imai
– volume: 176
  start-page: 5975
  year: 2006
  ident: B21
  article-title: OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity
  publication-title: J Immunol
  doi: 10.4049/jimmunol.176.10.5975
  contributor:
    fullname: Soroosh
– volume: 19
  start-page: 2132
  year: 2013
  ident: B6
  article-title: Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.ccr-12-1243
  contributor:
    fullname: Liu
– volume: 101
  start-page: 1291
  year: 2004
  ident: B17
  article-title: Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0306567101
  contributor:
    fullname: Bukczynski
– volume: 49
  start-page: 154
  year: 2014
  ident: B3
  article-title: Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line
  publication-title: Blood Res
  doi: 10.5045/br.2014.49.3.154
  contributor:
    fullname: Bae
– volume: 167
  start-page: 875
  year: 2001
  ident: B20
  article-title: Functional CD4 T cells after intercellular molecular transfer of 0X40 ligand
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.2.875
  contributor:
    fullname: Baba
– volume: 6
  start-page: 209
  year: 2018
  ident: B8
  article-title: The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.cir-17-0212
  contributor:
    fullname: Nuebling
– volume: 73
  start-page: 2598
  year: 2013
  ident: B11
  article-title: Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.can-12-2893
  contributor:
    fullname: Lim
– volume: 1441
  start-page: 167
  year: 2016
  ident: B9
  article-title: Expansion of NK cells using genetically engineered K562 feeder cells
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-3684-7_14
  contributor:
    fullname: Phan
– volume: 8
  start-page: 2278
  year: 2018
  ident: B7
  article-title: Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-20656-y
  contributor:
    fullname: Turaj
– volume: 229
  start-page: 173
  year: 2009
  ident: B19
  article-title: The significance of OX40 and OX40L to T-cell biology and immune disease
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2009.00766.x
  contributor:
    fullname: Croft
– volume: 68
  start-page: 421
  year: 2018
  ident: B15
  article-title: Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.10.021
  contributor:
    fullname: Pollmann
– volume: 5
  start-page: e1219007
  year: 2016
  ident: B14
  article-title: Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2016.1219007
  contributor:
    fullname: Granzin
– volume: 7
  start-page: e30264
  year: 2012
  ident: B5
  article-title: Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0030264
  contributor:
    fullname: Denman
– volume: 150
  start-page: 1705
  year: 1993
  ident: B2
  article-title: Costimulatory signals are required for optimal proliferation of human natural killer cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.150.5.1705
  contributor:
    fullname: Robertson
– volume: 29
  start-page: 187
  year: 2009
  ident: B22
  article-title: The role of OX40-mediated co-stimulation in T-cell activation and survival
  publication-title: Crit Rev Immunol
  doi: 10.1615/CritRevImmunol.v29.i3.10
  contributor:
    fullname: Redmond
SSID ssj0000493335
Score 2.5119174
Snippet Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new...
Background: Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we...
Background: Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 879
SubjectTerms expansion
IL-21
Immunology
K562
natural killer cells
OX40 ligand
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgEhIXxDfhS0biwiGqE48d5whlq6JW5VCQerPieEy3ahPE7krw75lxtqtdhMSFQy6OpVhvMvGb8eSNEG9jW2EbdCiR9tYSwJiy7ckfQ3IWYqgAkXO6R2fN6bn7OGOZnE2rL64Jm-SBJ-D2g1EWtQ2mdhGcDhSQuL6NqBvdQoMxf32V3QqmLifeq7U207kkRWHtfppfX6-4lIv1KR1Xbm3tQ1mu_28c889Sya295_C-uLcmjfL9tNgH4hYOD8WdqY3kr0fCz36ST3PaS45J5rS8PD2WB3h1tZC5JkAeEwFZD9DkXPtKo5_PQcmT-bduiJKvswsi4zxh5LyhXI7y00lZV4_F18PZl4Ojct04oezB1ssydk1qHQVi1qBlIySDiVBE11E4aILiv2cTcYUeUFV9apXDhE1tUs8-DvqJ2BvGAZ8JCdGp3pngiIcBJHChSV3P8tYAaLtUiHc3MPrvkz6Gp7iCIfcZcs-Q-wx5IT4wzpt5rGydB8jefm1v_y97F-LNjZU8eQIfb3QDjquFJ6JTKwoWbFOIp5PVNo_SFfczVlUhmh177qxl984wv8hq2xZaIk318_-x-BfiLsPBp1E1vBR7yx8rfCVuL-LqdX5_fwOF_PIj
  priority: 102
  providerName: Directory of Open Access Journals
Title Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21
URI https://www.ncbi.nlm.nih.gov/pubmed/31105701
https://search.proquest.com/docview/2232077267
https://pubmed.ncbi.nlm.nih.gov/PMC6491902
https://doaj.org/article/b506e36b528d483b8408c9de373947ed
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbdQKGX0nfdR1Chlx6ctS3Jko_tdkNK0rSQFnITljxKNuzaIbsL7b_vjGyHbOmpB19kGYtvNMxDo28Ye99UOVROuBTQtqZSKpVWHvXRBVPKxuUSgHK6R2f69Nx8nhNNjhrvwsSife8WB-1yddAuLmNt5fXKT8c6sen3r7NSVmjHiumETdA3vBOiX_UurxBC9UeSGIBV07BYrbZUxUXUlEYTUajIqb_t0AlmtEaRtP9fnubfBZN3LNDhI_ZwcB35x36Jj9k9aJ-w-30zyd9PmZ3_Qs2m5BfvAo_JeX56zGewXK55rAzgx-iGDAM4OVbA4ui3c5nxk8VF3TacnrNLdMlpQkfZQ77p-JeTtMifsZ-H8x-zo3Ron5B6WRabtKl1qAyGY6WCkkQRFIQSBJgag0LlMrpDG9Bj8BKy3IcqMxBAFyp40nQpnrO9tmvhJeOyMZk3yhlETcogjdOh9kRyLSWUdUjYhxFGe92zZFiMLgh9G9G3hL6N6CfsE-F8O4_4reNAd3NhBylbpzJcaelUYRpphMMw1PiqAaFFJTU0CXs3SsmiPtAhR91Ct11bdHeKDEOGUifsRS-121-NUk-Y3pHnzlp23-AWjJzbw5Z79d9fvmYPCAM6iCrkG7a3udnCWzZZN9v9mAfYj7v4D5PA9Ag
link.rule.ids 230,315,729,782,786,866,887,2106,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbWDsN22fuRPTVglx3c2JZky8ctS5EiaTagHdCbYMlSmyGxiyYBtn8_UraLZtipB19kGRb4iRJJUR8BPlVF4grDTeRwb42EkDIqLOqj8SoTlUmEcxTTnZzk8zP1bUw0ObK_CxOS9q1ZHNTL1UG9uAi5lZcrO-zzxIY_jkeZKHAfS4d7cBf1NY5vOOm_WqOXcy7bQ0l0wYqhX6xWW8rjInJKlRNVKE-owm1XC6bfjwJt__9szX9TJm_sQYePbjn6x_CwMzrZl_b1E7jj6qdwry1D-ecZ6PFvXBMobMYaz0JYn82nbOSWyzULOQVsigZM14CdQ-4stn4_EzGbLc7LumL0nFygMU8dGoo7sk3DjmZRmjyHn4fj09Ek6govRFZk6SaqytwXCh25TLqMQPTS-cxxp0p0J6WJ6fatR1vDChcn1hexct7lqfSW1gjBX8B-3dTuFTBRqdgqaRRKWwgvlMl9aYkeWwiXlX4An3vx68uWX0OjX0Ko6YCaJtR0QG0AXwmf637EjB0amqtz3UlYGxnjSDMjU1UJxQ06sMoWleM5L0TuqgF87NHVqEl0PFLWrtmuNRpKaYzORpYP4GWL9vWv-tkygHxnHuyMZfcNwh_Yuju4X9_6yw9wf3J6PNOzo_n0DTwgedBxVirewv7mauvewd662r4POvAXpjcIqQ
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYRSAuvB_laSQuHLJ52E6cI3Rb7aqlrLQg7c2KX7tFbVJtWwn-PTNOUm0RJzjk4kwUx5_HnhlPviHkgy1TV2qmIwd7a8S5EFFpQB-1lzm3OuXOYUz35LyYXcjjEdLk7Ep9haR9o-dH9WJ5VM-vQm7lamniPk8sPvsyzHkJ-1gWr6yPD8ht0Nkku-Go_2gNX8aYaA8mwQ0rYz9fLreYy4UElbJAulCWYpXbrh5MvycF6v6_2Zt_pk3e2IfGD_7jCx6S-53xST-1Io_ILVc_JnfacpS_nhA1-glrA4bPaONpCO_T2YQO3WKxpiG3gE7AkOkaQDjk0ELr1wue0On8sqotxev8Cox6FGgw_kg3DT2dRln6lHwfj74NT6KuAENkeJ5tIlsVvpTg0OXC5QimF87njjlZgVspdIJ_4XqwOQx3SWp8mUjnXZEJb3Ct4OwZOayb2r0glFuZGCm0hBHn3HOpC18ZpMnm3OWVH5CPPQRq1fJsKPBPEDkVkFOInArIDchnxGgnhwzZoaG5vlTdKCstEuhprkUmLZdMgyMrTWkdK1jJC2cH5H2PsAKNwmOSqnbNdq3AYMoScDryYkCet4jvXtXPmAEp9ubCXl_278AUCKzdHeQv__nJd-Tu2fFYTU9nk1fkHg4Hnmpl_DU53Fxv3RtysLbbt0ENfgMWCQsp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expansion+of+Human+NK+Cells+Using+K562+Cells+Expressing+OX40+Ligand+and+Short+Exposure+to+IL-21&rft.jtitle=Frontiers+in+immunology&rft.au=Kweon%2C+SoonHo&rft.au=Phan%2C+Minh-Trang+Thi&rft.au=Chun%2C+Sejong&rft.au=Yu%2C+HongBi&rft.date=2019-04-24&rft.eissn=1664-3224&rft.volume=10&rft.spage=879&rft.epage=879&rft_id=info:doi/10.3389%2Ffimmu.2019.00879&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon